MetaCap

Tempest Therapeutics (TPST) vs Universe Pharmaceuticals (UPC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Universe Pharmaceuticals (UPC) has outperformed Tempest Therapeutics (TPST) over the past year, losing 68.2% versus a loss of 91.8%. Over five years, TPST leads with a -99.8% price change compared with -100.0% for UPC. Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TPST-91.80%UPC-68.24%
+276%+83%-109%
Nov 21, 20251 yearNov 20, 2026
TPST-99.79%UPC-99.99%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TPST versus UPC key metrics
MetricTPSTUPC
Share price$0.287$1.08
Market cap$5.74M$5.43M
1-day change-6.18%-20.59%
YTD return-90.00%-71.65%
1-year return-91.80%-68.24%
5-year return-99.77%-99.99%
EPS (TTM)$-3.16$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$17.86B
Revenue growth (YoY)—-22.44%
Net income (latest FY)$-26.26M$-3.67B
Gross margin—35.28%
Operating margin—-16.33%
Net margin—-20.56%
52-week high$4.22$17.96
52-week low$0.28$1.05
Distance from 52-week high-93.20%-93.99%
Analyst consensusstrong_buy—
Avg. price target upside+2339.02%—
Average volume2.56M176.76K
Shares outstanding20.00M5.01M
Employees4216
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UPC has outperformed TPST by 23.6 percentage points over the past year.

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Universe Pharmaceuticals

UPC stock →

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications.

Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees

TPST vs UPC FAQ

Which is bigger, Tempest Therapeutics or Universe Pharmaceuticals?

Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.43M for Universe Pharmaceuticals (UPC).

Which stock has performed better over the past year, TPST or UPC?

UPC returned -68.24% over the past 12 months, compared with -91.80% for TPST (price return, excluding dividends). Past performance does not predict future results.

Are Tempest Therapeutics and Universe Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons